No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Eisai/Biogen’s Leqembi® (Lecanemab) Receives UK Marketing Approval for Early Alzheimer’s Disease
On 22 August 2024, Eisai and Biogen announced that Leqembi® (lecanemab) has received marketing authorisation from the UK’s MHRA for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease. The UK is the first country in Europe to...